Bumcrot D., 2006, Nat. Chem. Biol., 2, 711, 10.1038/nchembio839
Deleavey G. F., 2012, Chem. Biol., 19, 937, 10.1016/j.chembiol.2012.07.011
Novina C. D., 2004, Nature, 430, 161, 10.1038/430161a
Joshi B. H., 2014, Biotechnol. Genet. Eng. Rev., 30, 1, 10.1080/02648725.2014.921495
Karunapriyachitra, 2013, Int. J. Invent. Pharm. Sci., 1, 6
Li T., 2014, Nucleic Acid Ther., 24, 302, 10.1089/nat.2014.0480
Nielsen C., 2014, Expert Opin. Drug Delivery, 11, 791, 10.1517/17425247.2014.896898
Soni R. S., 2013, Int. Pharm. Sci., 3, 11
Meier M., 2000, J. Mol. Biol., 300, 857, 10.1006/jmbi.2000.3853
Grewal P. K., 2010, Methods Enzymol., 479, 223, 10.1016/S0076-6879(10)79013-3
Spiess M., 1990, Biochemistry, 29, 10009, 10.1021/bi00495a001
Nair J. K., 2014, J. Am. Chem. Soc., 136, 16958, 10.1021/ja505986a
Lonnberg H., 2009, Bioconjugate Chem., 20, 1065, 10.1021/bc800406a
Spinelli N., 2013, Chem. Soc. Rev., 42, 4557, 10.1039/C2CS35406C
http://www.alnylam.com/capella/presentations/positive-initial-revusiran-phase-2-data/.
Prakash T. P., 2014, Nucleic Acids Res., 42, 8796, 10.1093/nar/gku531
Meade B. R., 2014, Nat. Biotechnol., 32, 1256, 10.1038/nbt.3078
http://ir.regulusrx.com/releasedetail.cfm?ReleaseID=877462.
Yamada T., 2011, J. Org. Chem., 76, 1198, 10.1021/jo101761g
Manoharan M., 1995, Tetrahedron Lett., 36, 3647, 10.1016/0040-4039(95)00596-5
Carlile T. M., 2014, Nature, 515, 143, 10.1038/nature13802
Manoharan, M., Rajeev, K. G., Kelin, A. V., Takkellapati, S. R., and Matsuda, S.Nucleotides modified at the 2′-position of the sugar moiety for use in nucleic acids for therapeutic use. PCT Int. Appl. WO 2010101951, 2010.
Ramzaeva N., 2000, Helv. Chim. Acta, 83, 1108, 10.1002/1522-2675(20000607)83:6<1108::AID-HLCA1108>3.0.CO;2-9
Severgnini M., 2012, Cytotechnology, 64, 187, 10.1007/s10616-011-9407-0
